ClinicalTrials.gg
Active, not recruitingNCT07008144AldigoUpdated Oct 29, 2026

Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults

An interventional study of Digoxin alarm in Drug-Related Side Effects and Adverse Reaction and Digoxin Overdose, sponsored by Consorci Sanitari de l'Alt Penedès i Garraf. Active, not recruiting at 2 sites in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Consorci Sanitari de l'Alt Penedès i Garraf · Not applicable, Interventional, and Prevention

How we know

Updated Oct 29, 2026Now Active, not recruitingStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5,954
Allocation
Non-randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain — 6 open to participants now, 8 under way, none of them phase 3. Drug-Related Side Effects and Adverse Reactions · Spain.

Planned enrollment
2nd of 11
5,954 · median 290
Started
2025
with 2 others
No phase
5 of 16
2 open now
Registered
12th of 16
by date
Lead sponsor
1 of 16
Consorci Sanitari de l'Alt Penedès i Garraf

Among the 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain, this one is the 2nd largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 with no phase, and was the 12th registered.

Drug-Related Side Effects and Adverse Reactions

449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.

Browse Drug-Related Side Effects and Adverse Reactions studies →

Open to participants now

6 of the 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 56 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 38 (68%) set no upper age limit and 15 (27%) stop at 75 or younger; 15 take children under 18; 4 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Drug-Related Side Effects and Adverse Reactions with a site in Spain, or all of them as a file.
02

Study summary

The intervention consists of introducing computerized alerts into the electronic medical record of the CSAPG (MIRA software), which are triggered when a physician prescribes digoxin at a dose higher than the recommended amount (more than 0.125 mg/day).

The main objective of this study is to evaluate the effectiveness of a visible computerized alert aimed at physicians responsible for hospitalized elderly patients who have been prescribed digoxin at a dose higher than 0.125 mg/day (the recommended dose), in reducing the number of patients receiving inappropriate digoxin doses.

Read the detailed description

Intervention This quasi-experimental pre-post intervention study evaluates the effectiveness of computerized alerts integrated into the CSAPG electronic health record system (MIRA software). These alerts are triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.

Study Objective The main goal is to assess whether these alerts reduce the number of elderly hospitalized patients receiving inappropriate digoxin dosages.

Study Design and Duration The study will last 18 months in total, with a 12-month data collection period at each site (6 months before and 6 months after the intervention).

Sample Size and Population To detect a 25% reduction in inappropriate digoxin prescriptions with 80% power and a 0.05 alpha risk, the study requires 2,977 patients in both the pre- and post-intervention groups. Inclusion criteria include hospitalized men and women aged 65 and older. No patient exclusions are anticipated.

Statistical Analysis The primary analysis will compare the proportion of patients receiving digoxin doses above the recommended level before and after the intervention using the Chi-square test.

03

Conditions studied

  • Drug-Related Side Effects and Adverse Reaction
  • Digoxin Overdose

Keywords

  • digoxin
  • deprescription
  • Beers
  • computerized alerts
  • geriatrics
  • Elderly Hospitalized Patients
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women over 64 years of age.
  • Hospitalized in inpatient wards of the study centers during the study period.

Exclusion criteria

Exclusion Criteria:

  • Pacients under 64 years old
  • Patients without complete data available
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5,954 participants (estimated)

Study arms

  • No intervention
    Before intervention

    In this group, the outcome will be measured before the intervention is implemented at the center

  • Experimental
    Post intervention

    In this group, the outcome will be measured after the intervention is implemented at the center

    Other: Digoxin alarm

Interventions

  • OtherDigoxin alarm

    A computerized alert will be integrated into the CSAPG electronic health record system (MIRA software). These alerts will be triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.

06

What researchers measure

Primary outcomes

  1. Proportion of elderly inpatients receiving inappropriate digoxin doses

    Proportion of patients aged 65 and older who are prescribed digoxin at a dose higher than 0.125 mg/day during hospitalization. The outcome compares this proportion between the pre-intervention and post-intervention periods to evaluate the effectiveness of a computerized alert integrated into the electronic medical record system (MIRA).

    Time frame: From baseline to hospital discharge, as much 3 months

07

Study locations

2 sites
  • Consorci Sanitari Alt Penedès-Garraf-Hospital de Vilafranca
    Vilafranca del Penedès, Barcelona 08720, Spain
  • Consorci Sanitari Alt Penedès-Garraf Hospital Sant Camil
    Barcelona, Spain 08810, Spain
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

Supporting information: Study protocol

Time frame: After publication of main results of the study.

Access criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 17 months after the start.

Of 71 non-industry interventional studies with no phase under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 17 months is below that.

Counting every sponsor, half of 73 studies reached it within 26 months; a quarter within 12 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Nov 2026 → Jun 2027 and completion Nov 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jun 6, 2025
StartActual
Dec 31, 2025
Primary completionEst.
Jun 30, 2027was Nov 2026
CompletionEst.
Jun 30, 2027was Nov 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 29, 2026
Primary completion
Nov 30, 2026→Jun 30, 2027
Oct 29, 2026
Study completion
Nov 30, 2026→Jun 30, 2027
Oct 29, 2026
Documents
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Active, not recruiting
    Documents Study protocol ↗ posted
    Primary completion Nov 30, 2026→Jun 30, 2027
    Study completion Nov 30, 2026→Jun 30, 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07008144
Lead sponsor
Consorci Sanitari de l'Alt Penedès i Garraf
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
Dec 31, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Alejandro Rodríguez Molinero
study director · Consorci Sanitari de l'Alt Penedès i Garraf

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion